Press release —
Sigrid Therapeutics Launches on Fullscript, Expanding U.S. Practitioner Access
STOCKHOLM, Sweden, August 5, 2026 — Sigrid Therapeutics today announced the launch of its practitioner portfolio on Fullscript, North America's leading healthcare practitioner platform, marking an important commercial milestone in the company's U.S. growth strategy and significantly expanding access to its patented SiPore® technology platform.
The partnership provides Sigrid with immediate access to an established network of more than 125,000 healthcare providers serving over five million patients annually across North America. By joining Fullscript, Sigrid significantly expands its commercial reach through a trusted practitioner channel while simplifying product access for clinics across the United States.
The practitioner portfolio includes SiPore® Capsules, a dietary supplement designed for flexible everyday metabolic support, and SiPore® Liquid, a medical food delivering the highest-strength dose of patented SiPore® technology for maximum meal-by-meal metabolic support. Together, the products allow practitioners to tailor the use of SiPore® technology to different patient needs and clinical protocols.
The launch establishes Fullscript as Sigrid's first large-scale practitioner distribution platform in the United States, creating a scalable commercial channel for the company's patented SiPore® technology platform.
”Launching our practitioner portfolio on Fullscript represents an important milestone in Sigrid's U.S. commercial strategy," said Claus Kjærsgaard, Chief Executive Officer of Sigrid Therapeutics. "Healthcare practitioners are increasingly looking for evidence-based solutions that fit naturally into existing clinical workflows. Fullscript gives us immediate access to a highly engaged practitioner community and provides an efficient platform for expanding the reach of our patented SiPore® technology across the United States. This partnership strengthens our commercial platform and supports our ambition to establish SiPore® as a new category of gut-local metabolic health solutions.”
Meeting the Growing Demand for Earlier Metabolic Health Intervention
The launch comes at a time when metabolic healthcare is evolving, driven by greater use of continuous glucose monitoring (CGM), increased focus on post-meal metabolic health, and growing recognition of the value of earlier intervention.
This evolution reflects growing recognition that repeated exposure to the metabolic impact of everyday meals contributes to long-term metabolic dysfunction, creating demand for interventions that can be incorporated earlier in the patient journey.
With its patented gut-local technology platform, SiPore® is designed to support this emerging approach by helping reduce the metabolic impact of everyday meals during digestion without systemic absorption.
”Modern metabolic disease develops gradually over many years through repeated exposure to the metabolic impact of everyday meals," said Dr. Sanjay Bhojraj, a board-certified cardiologist and nationally recognized expert in preventive and integrative cardiovascular medicine. "Rather than focusing solely on downstream metabolic dysfunction, clinicians are increasingly interested in strategies that address the meal itself. Gut-local technologies like SiPore® provide an evidence-informed approach that complements nutrition, lifestyle interventions and broader metabolic care.”
Growing Scientific Validation
The commercial launch follows another significant milestone for Sigrid with the recent acceptance of the company's pivotal SHINE clinical study for publication in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science group.
The publication further strengthens the scientific foundation supporting Sigrid's commercial expansion into the U.S. practitioner market. Together, the SHINE publication and the Fullscript launch reinforce Sigrid's strategy of combining scientific credibility with commercial execution as the company expands its presence in the U.S. healthcare practitioner market.
Building a New Category in Metabolic Health
The availability of the SiPore® practitioner portfolio through Fullscript represents another important milestone in Sigrid's strategy to establish gut-local metabolic health solutions as a new category in metabolic care. By combining a differentiated technology platform, growing peer-reviewed clinical evidence and expanded commercial access, the company is positioning SiPore® for broader adoption among healthcare practitioners across the United States.
About SiPore®
SiPore® is Sigrid Therapeutics' patented gut-local technology platform designed to work during digestion by mechanically entrapping digestive enzymes involved in the breakdown of carbohydrates and fats. By slowing nutrient digestion, SiPore® supports steadier post-meal metabolic responses. The technology acts locally within the gastrointestinal tract and is not absorbed into the bloodstream.
About Fullscript
Fullscript is a health technology platform that helps providers and patients stay connected in the moments that matter most. Combining human guidance with technology shaped by real-world clinical expertise, Fullscript supports more than 125,000 providers and more than 5 million patients annually across North America with supplements, lab testing, clinical decision support and personalised care tools.
Related links
Topics
Categories
Sigrid Therapeutics is a Swedish health technology company developing gut-local metabolic health solutions powered by its patented SiPore® technology platform. The company's mission is to reduce the negative metabolic impact of modern meals through clinically evaluated, non-systemic technologies that complement nutrition, lifestyle interventions and broader metabolic care.
